The benefits of running trials in emerging markets are well known, for instance access to appropriate patients, lower costs and reduced turn-around times. However, working in emerging regions takes special planning and management processes that can be easily overlooked, which can lead to study delays, unnecessary expense or poor quality data. This webinar, presented from the viewpoint of a central laboratory and the lead CRO, will provide you with actionable tips and suggestions to use during your next trial.
Join ACM Global Central Lab and Pharm-Olam to learn the key considerations in working with outsourced partners in minimizing study start-up times, processing times and in optimizing work efficiencies.
- Operational considerations and best practice standard operating procedures.
- Strategies which support desired clinical outcomes.
- Effective methods to collaborate and communicate with your partner.
- Case Study Review: Working Together to Ensure Success – How Pharm-Olam and ACM Global Central Lab worked together to ensure an efficient partnership that provides quality data.
Mark Engelhart, Chief Commercial Officer, ACM Global Central Laboratory
Mark has more than 25 years’ experience within the Pharmaceutical and drug development industries, with extensive experience in sales, marketing, strategy, and global commercial operations. He has held commercial and general management roles across the continuum of drug development and commercialization, from pre-clinical and clinical development through post-approval marketing and sales. As Chief Commercial Officer, Mark manages the company’s global business development, marketing, commercial analysis, and bids & proposals functions.
Jerry Boxall, Managing Director, ACM Europe and Asia, ACM Global Central Laboratory
Trained as a Biomedical Scientist, Jerry has over 25 years of experience in this field. For the past 15 years, he has held senior central laboratory posts both in the UK and in Europe. Jerry has been heavily involved in the establishment of both European and global central laboratory networks and has been responsible for central laboratories in Germany, France, Denmark, The Netherlands, and the United Kingdom. Jerry joined the ACM team from CRL-Medinet in June 2000 as Head of European Operations, and took over as Managing Director, Europe, in January 2005.
Dr. Yamin “Mo” Khan, Executive VP of Global Clinical Development, Pharm-Olam International
Yamin ‘Mo’ Khan is the Executive VP of Global Clinical Development at Pharm-Olam International. He has a PhD in Biochemistry and has worked both in the CRO & the Pharmaceutical industries. He has been with the Pharm-Olam for 14 years working in Clinical Operations, Project Management and Business Development. As part of the Executive Committee, Mo is involved in strategic planning for Pharm-Olam and providing Executive oversight for ongoing projects.
Who Should Attend?
- Scientific Affairs Directors
- Medical Directors
- Principal Scientists
- Laboratory Operations
ACM Global Central Laboratory specializes in delivering high quality central laboratory testing services designed to optimize clinical trial outcomes. Through a powerful combination of robust global capabilities, operational and scientific expertise and unsurpassed service, ACM Global acts as an extension of our clients’ clinical teams to develop and execute Smarter Testing strategies that deliver reliable outcomes for their clinical development programs. Operating in more than 60 countries, ACM Global’s analytical team performs more than 15 million diagnostic tests each year from a test menu with more than 1,500 tests spanning all medical disciplines, including pathology, microbiology and molecular diagnostics, flow cytometry, specialized biomarkers, and pharmacogenomics.
Pharm-Olam International is a global contract research company with a presence in over 40 countries, offering a wide range of comprehensive, clinical research services to the Pharmaceutical, biotechnology, and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment, and meeting projected timelines. For more information, visit www.pharm-olam.com